Comparative Pharmacology
Head-to-head clinical analysis: DILANTIN 30 versus PRIMIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILANTIN 30 versus PRIMIDONE.
DILANTIN-30 vs PRIMIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by promoting sodium channel inactivation, thereby inhibiting repetitive firing of action potentials.
Primidone is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal inhibition. It also has active metabolites, phenobarbital and phenylethylmalonamide, which contribute to anticonvulsant effects.
300 mg/day orally in 3 divided doses (100 mg three times daily) or 300 mg/day once daily as an extended-release capsule. Loading dose: 1 g orally divided into three doses (400 mg, 300 mg, 300 mg) given at 2-hour intervals. Intravenous fosphenytoin loading dose: 15-20 mg PE/kg; maintenance: 4-6 mg PE/kg/day IV.
Initial: 100-125 mg orally at bedtime for 3 days; increase to 100-125 mg twice daily for 3 days, then 100-125 mg three times daily for 3 days; maintenance: 250 mg three times daily. Maximum: 500 mg four times daily.
None Documented
None Documented
Clinical Note
moderatePrimidone + Digoxin
"The metabolism of Digoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Torasemide
"The metabolism of Torasemide can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Etacrynic acid
"Primidone may increase the hypotensive activities of Etacrynic acid."
Terminal elimination half-life averages 22 hours (range 7–42 hours) in adults; dose-dependent due to saturable metabolism (Michaelis-Menten kinetics). At low concentrations, half-life is approximately 10–15 hours; at high concentrations, half-life may exceed 30 hours. Clinical context: steady state achieved in 5–10 days; half-life prolonged in neonates, elderly, and hepatic impairment.
Primidone: 10-12 hours; phenobarbital metabolite: 48-120 hours; PEMA: 16-18 hours. Steady-state requires 4-7 days for primidone but up to 2-3 weeks for phenobarbital accumulation.
Renal: ~70% (primarily as inactive metabolites including p-HPPH glucuronide, with <5% unchanged); Biliary/fecal: ~30% (enterohepatic circulation contributes to biliary excretion of metabolites and a small amount of unchanged drug).
Renal: approximately 40% unchanged, 30% as phenobarbital, 20% as phenylethylmalonamide (PEMA); fecal: <5%
Category C
Category D/X
Anticonvulsant
Anticonvulsant